In Brief: Subcutaneous Lecanemab (Leqembi Iqlik) for Initial Treatment of Alzheimer's Disease
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Regulatory update reports expanded subcutaneous lecanemab approval for initial therapy in Alzheimer's disease, highlighting an alternative to long-term intravenous infusions.
Key Points
Describe the FDA regulatory decision expanding the indication of subcutaneous lecanemab (Leqembi Iqlik) to include initiation dosing in Alzheimer's disease.
FDA regulatory review of the subcutaneous formulation of lecanemab (Leqembi Iqlik).
Assessment of once-weekly subcutaneous dosing schedules for treatment initiation in Alzheimer's disease.
The FDA approved subcutaneous lecanemab for once-weekly initiation dosing in patients with Alzheimer's disease.
The label expansion eliminates the prior restriction that required at least 18 months of intravenous lecanemab before switching to subcutaneous maintenance.